

To: [redacted] [redacted] [redacted] [redacted]@rivm.nl]
From: [redacted] [redacted]
Sent: Tue 1/14/2020 10:05:38 AM
Subject: Re: [ext] RE: Wuhan virus diagnostics
Received: Tue 1/14/2020 10:05:52 AM
[Wuhan virus assay V1\[3\].pdf](#)

Hi [redacted]

It is not necessary to do sensitivity testing, just focus on specificity. I will send you synthetic controls once they are ready, but you can just use diluted SARS-CoV RNA.

I encourage that you have your own primers designed and use your own pcr machines and even you own standard PCR reagents if different from ours. We want diversity of methods to challenge the robustness.

I will ask [redacted] to send you oligos from the original synthesis in case you have problems with yours (sometime the oligo factories screw up).

[redacted]

--

[redacted] [redacted]

[redacted] Charité Global Health

Charité - Universitätsmedizin Berlin
 Campus Charité Mitte

Chariteplatz 1
 D-10117 Berlin
 Germany

E-Mail: [redacted]@charite.de
<https://virologie-ccm.charite.de/>
<https://globalhealth.charite.de/>

Von: [redacted] [redacted] <[redacted]@rivm.nl>
Datum: Dienstag, 14. Januar 2020 um 10:39
An: [redacted] [redacted] <[redacted]@charite.de>
Betreff: [ext] RE: Wuhan virus diagnostics

Hi,

With respect to validation:

We ordered the primers/probes.

Do you wish for us to use your primer/probes or is that ok? Also will you share pos, synthetic control for the validation?

What would have the best added value for your study , also in light of what others will validate?

So, nr of ILI samples, known etiology/unknown etiology, what year? All possible.

Thanks [redacted]

From: [redacted] [redacted] <[redacted]@charite.de>
Sent: dinsdag 14 januari 2020 10:30
To: [redacted] [redacted] <[redacted]@rivm.nl>; support@ecdc.europa.eu; [redacted]@ecdc.europa.eu;
 [redacted]@ecdc.europa.eu; [redacted]@ecdc.europa.eu
Cc: [redacted]@univ-amu.fr
Subject: Wuhan virus diagnostics

Dear All,

Here is a validated Wuhan virus assay that we will communicate via the WHO website today. Just FYI. We are providing full lab support. Control material will be distributed via EVAg (coordinator in CC).

5.1.2e

5.1.2e 5.1.2e

5.1.2e Charité Global Health

Charité - Universitätsmedizin Berlin
Campus Charité Mitte

Chariteplatz 1
D-10117 Berlin
Germany

E-Mail: 5.1.2e@charite.de
<https://virologie-ccm.charite.de/>
<https://globalhealth.charite.de/>

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.
www.rivm.nl De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.
www.rivm.nl/en Committed to *health and sustainability*